Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba

Lack of technology transfer stands out as a formidable barrier

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia

India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind

Venus Remedies earns REO Certification from CII for second consecutive year

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)

Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi

RHTC will address a long-standing healthcare access issue for all the local population

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients